Pulse Biosciences Q3 2026 Earnings Call - PULSE BIOSCIENCES INC

Explicit Guidance:

• Revenue/Expenses: No explicit numerical revenue or earnings guidance provided for specific future periods; management states they will not provide specific revenue numbers until after commercial launch readiness is established.
• Cost Growth: Expect quarterly non-GAAP costs and expenses to increase by 15% to 25% above the Q2/Q3 2026 average of approximately $20 million in the coming quarters.
• Cash Runway: Cash and marketable securities of $189 million provide approximately two years of cash runway; remaining ATM capacity is $64 million.
• Gross Margins: Anticipate gross margins on disposables will exceed 70% at scale.

Business-Segment Outlook:

• NPulse Cardiac Catheter (AFib):
  • Timeline: Expected to receive final patient data (blended 6-month/12-month follow-up) in Q3 2027 for FDA PMA submission; anticipate CE mark approval in Q4 2027.
  • Commercial Launch: Planning for a launch beginning in early 2028.
  • Enrollment: Completed enrollment of 169 evaluable patients (189 total) for the pivotal US IDE study three months ahead of schedule.
  • Next Gen Catheter: Expects first-in-human evaluations for the next-generation catheter (combining circumferential and focal ablation) in 2027.
  • Persistent AF: Intends to submit IDE application for a persistent AF study in Q4 2026.
• Surgical Clamp (Nanoclip AF):
  • Enrollment: On track to complete enrollment by end of 1H 2027.
  • Regulatory: Anticipate CE mark approval in Q4 2027.
  • Expansion: Plans to evaluate the platform for prophylactic use (preventing post-operative AFib) in the future, potentially expanding the market beyond concomitant use.
• Vibrance (Thyroid):
  • Timing: Additional data readouts from the PRECISE-BTN study expected as patients complete 6-month and 12-month follow-ups during 2027 to support a 510K submission for benign thyroid nodules.
  • New Indications: Advancing a Phase 1 feasibility study for primary hyperthyroidism (15 patients) and a study for papillary thyroid microcarcinoma (up to 30 patients).
  • Registry: Plans to commence a real-world registry and a formal controlled study for benign thyroid nodules in partnership with the Clayman Thyroid Center.
  • Future Pipeline: Exploring NSPFA applications for parathyroid disease and ventricular tachycardia (VT)/premature ventricular contractions (PVCs), though these remain in the research phase.

Market and Competitive Outlook:

• Market Share: Anticipates rapid market share shifts toward NSPFA due to workflow efficiency, reduced learning curve, and superior clinical outcomes (90%+ freedom from AFib), expecting share gains to be durable due to the patent moat and lack of competing nanosecond technology.
• Competitive Landscape: Views the market as shifting rapidly from microsecond PFA (MSPFA) and RF to NSPFA; notes that competitors (Boston Scientific, Medtronic) have shifted share but cannot replicate the specific mechanistic differentiation of NSPFA (cell killing vs. stunning).
• Reimbursement/Policy: Expects Medicare's MPPR (Multiple Procedure Payment Reduction) policy and hospital economics to favor NSPFA due to procedural efficiency, faster turnover, and potential for concomitant procedures (e.g., Left Atrial Appendage Closure).
• Mapping Integration: Plans to expand integration beyond the Abbott EnSite system to include top mapping systems like CARTO and others to ensure broad market adoption.

Macro / Industry Outlook:

• Adoption Trends: Anticipates high demand and physician enthusiasm driven by the "five-second" delivery capability and intuitive workflow, which reduces procedural time (some cases under 7 minutes).
• Clinical Standard: Management views the technology as a potential new worldwide standard for AFib ablation, aiming to move from a niche technology to a primary treatment modality.
• Partnership Environment: Maintains an open stance toward partnerships (licensing, co-promotion) or direct launch depending on valuation and compensation terms; notes that strategic partners are currently waiting for definitive clinical data before committing to high valuations.

Strategic Initiatives:

• Commercial Readiness: Investing capital in scaling manufacturing (vertical integration for consoles, contract manufacturing for catheters), specifically transitioning from 1 to 4 production lines across multiple locations.
• Team Building: Hiring senior management with launch experience (under COO and CTO) and a senior manufacturing lead with 15 years of catheter experience.
• Evidence Generation: Submitting 100+ patients with 12-month follow-up data at the AF Symposium in early 2027; continuing modular submissions for regulatory clearance.
• Capacity Expansion: Allocating a portion of the $189M cash balance to increase production output potential and process efficiency to support high volume and margin expansion.

Risks and Headwinds to Outlook:

• Regulatory Timing: Final data readout and FDA/CE approval timelines (targeted for late 2027) remain subject to regulatory review delays.
• Manufacturing Scale: Scaling production from IDE volumes to commercial levels requires successful process transfer and yield management; risks include the challenge of increasing output by 200-300x.
• Safety/Technical Risks: Potential for hemolysis (elevated kidney markers) at higher dosing levels, though management notes this is manageable via fluid infusion protocols and is not expected to be a critical issue in the IDE.
• Data Variability: Uncertainty regarding whether the US pivotal study results will exactly match European feasibility data, though early trends are highly consistent.
• Competitive Response: While management believes NSPFA is unique, they acknowledge competitors may attempt to follow with their own products, though they argue NSPFA's patent moat and "first-mover" clinical data create a defensible position.

Management Tone on the Future:

• Confidence: Highly confident ("extremely proud," "exceptional," "unprecedented") in the technology's differentiation, speed of enrollment, and clinical efficacy data.
• Strategic Shift: Tone indicates a shift from pure R&D to "pre-commercial readiness," focusing heavily on supply chain, manufacturing scale, and market segmentation.
• Capital Discipline: Expresses comfort with the current balance sheet and financing flexibility, emphasizing the ability to fund milestones without immediate pressure for revenue generation.
• Differentiation: Repeatedly emphasizes that NSPFA is a distinct category ("Sherbet vs. Ice Cream") compared to microsecond PFA, expecting durable market share rather than transient shifts.

Miscellaneous:

• Patent Protection: Cites a "patent moat" of over 285 owned patents protecting the NSPFA platform and delivery systems.
• Dilution: Cumulative dilution from ATM program since May 2026 remains under 6%.
• Safety Mitigation: Protocols for the IDE study include pre-procedure fluid infusion to mitigate hemolysis risks, a step not present in the earlier feasibility study.